Truvian Health vs Tempus
Side-by-side comparison of AI visibility scores, market position, and capabilities
Truvian Health received FDA 510(k) clearance for its TruVerus benchtop blood analyzer in Dec 2025; raised $74M in July 2024 and is partnering with Shoppers Drug Mart for commercial rollout.
About
Truvian Health is a San Diego-based medical diagnostics company developing an automated benchtop blood testing platform that delivers lab-accurate results from a few drops of blood in under 30 minutes — without requiring trained laboratory personnel. The company's flagship product, TruVerus, combines multiple blood test modalities into a single compact analyzer designed for point-of-care settings such as physician offices, clinics, urgent care centers, and long-term care facilities that lack on-site labs.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
About
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.